Edition:
United States

Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

32.91USD
3:59pm EDT
Change (% chg)

$-99.69 (-75.18%)
Prev Close
$132.60
Open
$33.08
Day's High
$33.08
Day's Low
$32.71
Volume
134,107
Avg. Vol
270,285
52-wk High
$34.76
52-wk Low
$22.88

Latest Key Developments (Source: Significant Developments)

Bayer gets positive CHMP opinion to update rivaroxaban's label
Friday, 15 Sep 2017 08:03am EDT 

Sept 15 (Reuters) - BAYER AG ::RECEIVES POSITIVE CHMP OPINION FOR RIVAROXABAN 10 MG ONCE DAILY FOR EXTENDED PREVENTION OF VENOUS THROMBOEMBOLISM.‍FINAL EUROPEAN COMMISSION DECISION EXPECTED BY NOVEMBER 2017​.  Full Article

FDA approves new treatment for adults with relapsed follicular lymphoma
Thursday, 14 Sep 2017 01:02pm EDT 

Sept 14 (Reuters) - U.S. Food and Drug Administration::U.S. FDA approves new treatment for adults with relapsed follicular lymphoma.Granted the approval of Aliqopa to Bayer Healthcare Pharmaceuticals, Inc​.Granted accelerated approval to Aliqopa for treatment of adults with relapsed follicular lymphoma who have received at least 2 prior treatments.  Full Article

Bayer and Ginkgo Bioworks join forces for sustainable agriculture
Thursday, 14 Sep 2017 07:01am EDT 

Sept 14 (Reuters) - Bayer Ag ::Bayer and Ginkgo Bioworks join forces for sustainable agriculture, forming new company with usd 100 million series a.Bayer AG - ‍Bayer and Ginkgo bioworks will create a new company focused on plant microbiome​.  Full Article

ASML announces CFO Wolfgang Nickl to leave by end of April 2018‍
Tuesday, 12 Sep 2017 06:02am EDT 

Sept 12 (Reuters) - ASML HOLDING NV ::CFO WOLFGANG NICKL TO LEAVE ASML BY THE END OF APRIL 2018‍​.‍WOLFGANG NICKL WILL JOIN GERMAN LIFE SCIENCE COMPANY BAYER <<>> AS ITS NEW CFO.​.  Full Article

Bayer and Vanderbilt University Medical Center agree five-year research alliance
Monday, 11 Sep 2017 08:05am EDT 

Sept 11 (Reuters) - BAYER AG ::‍BAYER AND VANDERBILT UNIVERSITY MEDICAL CENTER COLLABORATE TO DEVELOP THERAPIES AGAINST KIDNEY DISEASES​.‍BAYER WILL HAVE AN OPTION FOR EXCLUSIVE USE OF COLLABORATION RESULTS​.AGREED ON A FIVE-YEAR STRATEGIC RESEARCH ALLIANCE TO JOIN FORCES IN FIGHT AGAINST KIDNEY DISEASES.‍FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED​.  Full Article

Bayer submits U.S. license application for Hemophilia treatment
Thursday, 31 Aug 2017 12:35am EDT 

Aug 31 (Reuters) - Bayer AG :Says submits biologics license application in U.S. for BAY94-9027.  Full Article

Bayer says will continue to work with European Commission
Tuesday, 22 Aug 2017 09:03am EDT 

Aug 22 (Reuters) - Bayer Ag :‍confirmed that european commission has initiated a phase ii investigation of proposed combination of bayer and monsanto.says will continue to work constructively with the European Commission​.  Full Article

Bayer and SICIT 2000 sign exclusive distribution agreement‍​
Friday, 11 Aug 2017 08:43am EDT 

Aug 11 (Reuters) - BAYER AG :BAYER AND SICIT 2000 SIGN EXCLUSIVE DISTRIBUTION AGREEMENT‍​.FINANCIAL TERMS WERE NOT DISCLOSED‍​.UNDER THE AGREEMENT, BAYER WILL COMMERCIALIZE BAYFOLAN COBRE AND BAYFOLAN AKTIVATOR FOR FOLIAR USES IN VARIOUS CROPS WORLDWIDE.  Full Article

Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
Wednesday, 26 Jul 2017 07:09am EDT 

July 26 (Reuters) - Compugen Ltd ::Compugen discloses updates to collaborative activities with bayer in immuno-oncology.Compugen - agreement with Bayer AG involves research, development, commercialization of antibody-based therapeutics against cgen-15001t and cgen-15022.Compugen Ltd - it has been determined current collaboration will focus solely on cgen-15001t, all rights to cgen-15022 will be returned to Compugen.  Full Article

Bayer invests 92 million euros in Animal Health production
Monday, 3 Jul 2017 05:03am EDT 

July 3 (Reuters) - BAYER AG :INVESTS 92 MILLION EUROS IN ANIMAL HEALTH PRODUCTION.PROGRAM FOR EXPANDING SITE IN KIEL, GERMANY, UNTIL 2021.  Full Article

Photo

Bayer says needs more time for Monsanto deal approval

MONHEIM, Germany German drugs and pesticides group Bayer said on Tuesday it was now likely to be early next year before it can complete its $66 billion deal to acquire U.S. group Monsanto , later than previously expected.